

# 28 Er Antigens

28.1 Introduction, 493  
28.2 Er antigens, 493

28.3 Antibodies, 494

## 28.1 Introduction

$Er^a$  and  $Er^b$ , the products of alleles, are high and low frequency antigens, respectively;  $Er3$  is defined by an antibody produced by an  $Er(a-b-)$  individual. These three antigens constitute collection 208 of the ISBT terminology, the Er collection:  $Er^a$  is ER1 (208001);  $Er^b$  is ER2 (208002); and  $Er3$  is ER3 (208003).

## 28.2 Er antigens

### 28.2.1 $Er^a$ and $Er^b$ (ER1 and ER2): inheritance and frequencies

Families of two of the original three  $Er(a-)$  phenotypes described by Daniels *et al.* [1] in 1982 showed  $Er(a-)$  to be an inherited character. In 1988, Hamilton *et al.* [2] described an antibody to a low frequency antigen, named  $Er^b$ , that reacted with five of six  $Er(a-)$  red cell samples. In one family the presence of  $Er(a-)$  in two generations resulted from an  $Er(a-b+) \times Er(a+b+)$  mating [2].  $Er^a$  and  $Er^b$ , therefore, appear to be inherited regularly as co-dominant alleles. Family studies have shown that Er is not part of the ABO, MNS, P1PK, Duffy, Kidd, or Dombrock systems [1–3].

$Er(a-)$  phenotype has only been found in people of European origin ([1,4–6] and several other unpublished examples), including a Mexican family [7], although an abnormal  $Er(a-)$  phenotype was identified in a Japanese family [3] (see below). No  $Er(a-)$  individual was found in tests on red cells from 63 762 mostly white [1,4,8] and 13 521 Japanese [3] blood donors.

Four of 605 random white donors were  $Er(b+)$  and the frequency of the  $Er^b$  allele is calculated as 0.0033 [2]. If the existence of a third allele is disregarded, the  $Er^a$  allele has a frequency of 0.9967 and  $Er(a-)$  would only be expected in about 1 in 100 000 white people.

Red cells of a Japanese woman and two of her siblings were negative with five anti- $Er^a$  (including the original), but reacted with three others [3]. Positive and negative results were confirmed by adsorption techniques. The serum of the proband, who had been transfused twice and pregnant three times, contained an antibody that resembled anti- $Er^a$ : it reacted with all cells except  $Er(a-b+)$  cells and those of the proband and two of her siblings.

### 28.2.2 $Er3$

$Er(a-b-)$  phenotype has been identified in two unrelated individuals and an  $Er(a+b-)$  daughter had an  $Er(a-b+)$  mother, suggesting the presence of a third allele [2,9]. One of the  $Er(a-b-)$  individuals, a Caucasian man with consanguineous parents, had an antibody, named anti- $Er3$ , that reacted with all red cells tested, including  $Er(a-)$  cells [9]. Anti- $Er3$  reacted with the red cells of the other  $Er(a-b-)$  person, suggesting that the man with anti- $Er3$  may have an  $Er$ -null phenotype, whereas the other  $Er(a-b-)$  individual could have another active allele that produces neither  $Er^a$  nor  $Er^b$ .

### 28.2.3 Antigen characteristics

$Er^a$  is fully expressed on cord cells and is not sensitive to the treatment of red cells with proteases (trypsin, chymotrypsin, papain, ficin, pronase), sialidase, or the

disulphide bond reducing agent AET. Incubation of red cells in low pH EDTA/glycine buffers, often used in antibody-elution tests, resulted in loss of Er<sup>a</sup> and Er<sup>3</sup> [9,10]. There was total loss of Er<sup>a</sup> at pH 2.0, partial loss at pH 2.5, and no apparent loss at pH 3.0 [10].

Er<sup>b</sup> is resistant to treatment of red cells with ficin, papain, or DTT [2].

### 28.3 Antibodies

All the recorded producers of anti-Er<sup>a</sup> have been transfused and/or pregnant [1,3–7,11]. The antibodies are IgG and do not fix complement [1,3,4,7]. In two patients with anti-Er<sup>a</sup>, Er(a+) red cells gave a positive DAT after transfusion, but there were no signs of haemolysis [1,4]. The patient with anti-Er<sup>3</sup> showed signs suggesting mild haemolysis following transfusion of one unit of incompatible red cells [9]. Monocyte phagocytosis assays and *in vivo* red cell survival studies provided additional evidence that Er<sup>a</sup> antibodies are not clinically significant [1,4,7], but that the anti-Er<sup>3</sup> was potentially significant [9]. Red cells of three babies born to women with anti-Er<sup>a</sup> gave positive DATs, but none had HDFN [1,6,11].

The producers of the only two known anti-Er<sup>b</sup> had been pregnant, but not transfused; both had Er(a+b+) husbands [2,12]. Er(b+) red cells from babies of both of the women with anti-Er<sup>b</sup> gave strongly positive DATs, but there were no other indications of HDFN.

### References

- 1 Daniels GL, Judd WJ, Moore BPL, *et al.* A 'new' high frequency antigen Er<sup>a</sup>. *Transfusion* 1982;22:189–193.
- 2 Hamilton JR, Beattie KM, Walker RH, Hartrick MB. Er<sup>b</sup>, an allele to Er<sup>a</sup>, and evidence for a third allele, Er. *Transfusion* 1988;28:268–271.
- 3 Naoki K, Okuma S, Uchiyama E, *et al.* Er(a–) red cell phenotype in Japan. *Transfusion* 1991;31:572–573.
- 4 Thompson HW, Skradski KJ, Thoreson JR, Polesky HF. Survival of Er(a+) red cells in a patient with allo-anti-Er<sup>a</sup>. *Transfusion* 1985;25:140–141.
- 5 Lylloff K, Georgsen J, Grunnet N, Jersild C. On the inheritance of the Er<sup>a</sup> red cell antigen. *Transfusion* 1987;27:118.
- 6 Rowe GP. On the inheritance of Er and the frequency of Er<sup>a</sup>. *Transfusion* 1988;28:87–88.
- 7 Long W, Steinmetz CL, Aranda LL, *et al.* The first reported example of anti-Er<sup>a</sup> in a patient of Mexican descent. *Vox Sang* 2010;99(Suppl. 1):333–334 [Abstract].
- 8 Gale SA, Rowe GP, Northfield FE. Application of a microtitre plate antiglobulin technique to determine the incidence of donors lacking high frequency antigens. *Vox Sang* 1988;54:172–173.
- 9 Arriaga F, Mueller A, Rodberg K, *et al.* A new antigen of the Er collection. *Vox Sang* 2003;84:137–139.
- 10 Liew YW, Uchikawa M. Loss of Er<sup>a</sup> antigen in very low pH buffers. *Transfusion* 1987;27:442–443.
- 11 Needs M, Poole J, Warke N, *et al.* A case of anti-Er<sup>a</sup> in pregnancy. *Transfus Med* 2007;17(Suppl. 1):41 [Abstract].
- 12 Poole J, Cordoba R, Marais I, *et al.* The second example of anti-Er<sup>b</sup> and its clinical significance in pregnancy. *Vox Sang* 2010;99(Suppl. 1):340 [Abstract].